Comparison of Fluconazole and Nystatin Oral Suspensions for Prophylaxis of Systemic Fungal Infection in Very Low Birthweight Infants

 

 Buy Article Permissions and Reprints

ABSTRACT

We compared the efficacy and safety of fluconazole and nystatin oral suspensions for the prevention of systemic fungal infection (SFI) in very low birthweight infants. A prospective, randomized clinical trial was conducted over a 15-month period, from May 1997 through September 1998, in 80 preterm infants with birthweights <1500 g. The infants were randomly assigned to receive oral fluconazole or nystatin, beginning within the first week of life. Prophylaxis was continued until full oral feedings were attained. Blood and urine cultures were obtained at enrollment and then weekly thereafter. Thirty-eight infants were randomly assigned to receive oral fluconazole (group I), and 42 infants were assigned to receive nystatin (group II). Birthweight, gestational age, and risk factors for fungal colonization and SFI at the time of randomization and during the hospital course were similar in both groups. SFI developed in two infants (5.3%) in group I and six infants (14.3%) in group II. The difference between these two rates was not statistically significant (relative risk, 0.37; 95% confidence interval, 0.08 to 1.72). There were no deaths in group I and six deaths in group II (p = 0.03). Two infants died of neonatal sepsis, and four deaths were related to necrotizing enterocolitis and/or spontaneous intestinal perforation. No deaths were due to SFI. Enrollment was halted before completion and the study did not attain adequate power to detect a hypothesized drop in SFI rate from 15 to 5%. Although the results cannot justify any conclusion about the relative efficacy of fluconazole versus nystatin in prevention of SFI, the significantly higher mortality rate in the nystatin group raises questions about the relative safety of this medication.

REFERENCES

• 1 Stoll B J, Hansen N, Fanaroff A A et al.. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.  Pediatrics. 2002;  110(2 Pt 1) 285-291
  CrossrefPubMedGoogle Scholar
• 2 Makhoul I R, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey.  Pediatrics. 2002;  109(1) 34-39
  CrossrefPubMedGoogle Scholar
• 3 Kossoff E H, Buescher E S, Karlowicz M G. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases.  Pediatr Infect Dis J. 1998;  17(6) 504-508
  CrossrefPubMedGoogle Scholar
• 4 Fanaroff A A, Korones S B, Wright L L The National Institute of Child Health and Human Development Neonatal Research Network et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants.  Pediatr Infect Dis J. 1998;  17(7) 593-598
  CrossrefPubMedGoogle Scholar
• 5 Benjamin Jr D K, Stoll B J, Fanaroff A A National Institute of Child Health and Human Development Neonatal Research Network et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.  Pediatrics. 2006;  117(1) 84-92
  CrossrefPubMedGoogle Scholar
• 6 Saiman L, Ludington E, Pfaller M et al.. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.  Pediatr Infect Dis J. 2000;  19(4) 319-324
  CrossrefPubMedGoogle Scholar
• 7 Mittal M, Dhanireddy R, Higgins R D. Candida sepsis and association with retinopathy of prematurity.  Pediatrics. 1998;  101(4 Pt 1) 654-657
  CrossrefPubMedGoogle Scholar
• 8 Friedman S, Richardson S E, Jacobs S E, O'Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome.  Pediatr Infect Dis J. 2000;  19(6) 499-504
  CrossrefPubMedGoogle Scholar
• 9 Faix R G, Kovarik S M, Shaw T R, Johnson R V. Mucocutaneous and invasive candidiasis among very low birth weight (less than 1,500 grams) infants in intensive care nurseries: a prospective study.  Pediatrics. 1989;  83(1) 101-107
  PubMedGoogle Scholar
• 10 Rowen J L, Rench M A, Kozinetz C A, Adams Jr J M, Baker C J. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates.  J Pediatr. 1994;  124(5 Pt 1) 789-794
  PubMedGoogle Scholar
• 11 Austin N C, Darlow B. Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants.  Cochrane Database Syst Rev. 2004;  (1) CD003478
  PubMedGoogle Scholar
• 12 McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants.  Cochrane Database Syst Rev. 2004;  (1) CD003850
  PubMedGoogle Scholar
• 13 Sims M E, Yoo Y, You H, Salminen C, Walther F J. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants.  Am J Perinatol. 1988;  5(1) 33-36
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Ozturk M A, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit.  Mycoses. 2006;  49 484-492
  CrossrefPubMedGoogle Scholar
• 15 Kaufman D, Boyle R, Hazen K C, Patrie J T, Robinson M, Donowitz L G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants.  N Engl J Med. 2001;  345(23) 1660-1666
  CrossrefPubMedGoogle Scholar
• 16 Kicklighter S D, Springer S C, Cox T, Hulsey T C, Turner R B. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant.  Pediatrics. 2001;  107(2) 293-298
  CrossrefPubMedGoogle Scholar
• 17 Manzoni P, Arisio R, Mostert M et al.. Prophylactic fluconazole is effective in preventing fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study.  Pediatrics. 2006;  117 e22-e32
  CrossrefPubMedGoogle Scholar
• 18 Uko S, Soghier L M, Vega M et al.. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.  Pediatrics. 2006;  117(4) 1243-1252
  CrossrefPubMedGoogle Scholar
• 19 Bertini G, Perugi S, Dani C, Filippi L, Prates S, Rubaltelli F F. Fluconazole prophylaxis prevents invasive fungal invasive infection in high-risk, very low birth weight infants.  J Pediatr. 2005;  147 162-165
  CrossrefPubMedGoogle Scholar
• 20 Healy C M, Baker C J, Zaccaria E, Campbell J R. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit.  J Pediatr. 2005;  147(2) 166-171
  CrossrefPubMedGoogle Scholar
• 21 Burwell L A, Kaufman D, Blakely J, Stoll B J, Fridkin S K. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices.  Pediatrics. 2006;  118(4) e1019-e1026
  CrossrefPubMedGoogle Scholar
• 22 U.S. Food and Drug Administration .Approval letter, final printed labeling, and chemistry review(s). Nystatin oral suspension USP. Approval date: June 25, 1998. http://Available at www.fda.gov/cder/foi/anda/98/64142.htm Accessed April 14, 2009
  Google Scholar
• 23 Antifungal agents for common paediatric infections.  Paediatr Child Health. 2007;  12(10) 875-883
  PubMedGoogle Scholar
• 24 Mutz A E, Obladen M W. Hyperosmolar oral medication and necrotizing enterocolitis.  Pediatrics. 1985;  75(2) 371-372
  PubMedGoogle Scholar
• 25 Novelli V, Holzel H. Safety and tolerability of fluconazole in children.  Antimicrob Agents Chemother. 1999;  43(8) 1955-1960
  PubMedGoogle Scholar
• 26 Charlier C, Hart E, Lefort A et al.. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?.  J Antimicrob Chemother. 2006;  57(3) 384-410
  CrossrefPubMedGoogle Scholar
• 27 Flynn P M, Cunningham C K, Kerkering T The Multicenter Fluconazole Study Group et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin.  J Pediatr. 1995;  127(2) 322-328
  PubMedGoogle Scholar
• 28 Groll A H, Just-Nuebling G, Kurz M et al.. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer.  J Antimicrob Chemother. 1997;  40(6) 855-862
  CrossrefPubMedGoogle Scholar
• 29 Kaufman D, Fairchild K D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.  Clin Microbiol Rev. 2004;  17(3) 638-680
  CrossrefPubMedGoogle Scholar
• 30 Aghai Z H, Mudduluru M, Nakhla T A et al.. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis.  J Perinatol. 2006;  26(9) 550-555
  CrossrefPubMedGoogle Scholar

Kimon ViolarisM.D. 

Division of Neonatology, Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian

Columbia University Medical Center, 3959 Broadway, CHN 12-1202, New York, NY 10032-3784

Email: kv2145@columbia.edu